Navigation Links
FDA Approves Ferriprox to Treat Patients with Excess Iron in the Body
Date:10/14/2011

SILVER SPRING, Md., Oct. 14, 2011 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved Ferriprox (deferiprone) to treat patients with iron overload due to blood transfusions in patients with thalassemia, a genetic blood disorder that causes anemia, who had an inadequate response to prior chelation therapy.

(Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO)

Patients with thalassemia have excess iron in the body from the frequent blood transfusions (transfusional iron overload), a condition that is serious and can be fatal.  These patients also have a risk of developing liver disease, diabetes, arthritis, heart failure or an abnormal heart rhythm.  

The standard of care to treat transfusional iron overload is chelation therapy – chemical agents that are used to remove heavy metals from the body. Ferriprox is intended for use when chelation therapy is inadequate.

"Ferriprox represents the first new FDA-approved treatment for this disorder since 2005," said Richard Pazdur, M.D., director of the Office of Hematology and Oncology Products in the FDA's Center for Drug Evaluation and Research.

The safety and effectiveness of Ferriprox is based on an analysis of data from twelve clinical studies in 236 patients. Patients participating in the study did not respond to prior iron chelation therapy.  Ferriprox was considered a successful treatment for patients who experienced at least a 20 percent decrease in serum ferritin, a protein that stores iron in the body for later use. Half of the patients in the study experienced at least a 20 percent decrease in ferritin levels.

The most common side effects seen in patients who received Ferriprox included nausea, vomiting, abdominal and joint pain, urine discoloration (chromaturia), a decrease in the number of white blood cells (neutropenia), and an increase in
'/>"/>

SOURCE U.S. Food and Drug Administration
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
2. Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
3. FDA Approves Cymbalta(R) for Maintenance Treatment of Major Depressive Disorder
4. European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection
5. FDA Approves MiddleBrooks Amoxicillin PULSYS for Pharyngitis/Tonsillitis in Adolescents and Adults
6. FDA Approves XYZAL(R) (levocetirizine dihydrochloride) Oral Solution for the Relief of Seasonal and Year Round Allergies and Chronic Idiopathic Urticaria
7. UM Maryland Industrial Partnerships Program Approves 18 Collaborative Research Projects, Worth $4.4 Million, Between University Faculty, State Technology Companies
8. U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age)
9. U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older
10. FDA Approves HIFU Clinical Trial for Recurrent Prostate Cancer
11. EPA Approves XDS-CALUX(R) as Alternate Dioxin Test Method 4435
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... , July 29, 2014 Regado Biosciences, ... focused on the Phase 3 clinical development of Revolixys™ ... antithrombotic drug system, today announced that it will hold ... Aug. 12, 2014, at 8:30 a.m. EDT to discuss ... Interested participants and investors may access the ...
(Date:7/29/2014)... Edwards Lifesciences Corporation (NYSE: EW ), ... hemodynamic monitoring, today reported net income for the quarter ended ... share, and non-GAAP net income of $94.0 million, or $0.88 ... year earlier was $93.3 million, or $0.81 per diluted share, ... diluted share.  Net sales for the quarter ...
(Date:7/29/2014)... 2014 New technology in the form of ... to see and assess brain tissue more clearly while ... authors who released their findings today at the Society ... in Colorado Springs, CO. ... neurointervention, a specialty that facilitates stroke treatment by navigating ...
Breaking Medicine Technology:Regado Biosciences to Provide Second Quarter 2014 Financial Results and Corporate Highlights 2Regado Biosciences to Provide Second Quarter 2014 Financial Results and Corporate Highlights 3Edwards Lifesciences Reports Strong Second Quarter Results 2Edwards Lifesciences Reports Strong Second Quarter Results 3Edwards Lifesciences Reports Strong Second Quarter Results 4Edwards Lifesciences Reports Strong Second Quarter Results 5Edwards Lifesciences Reports Strong Second Quarter Results 6Edwards Lifesciences Reports Strong Second Quarter Results 7Edwards Lifesciences Reports Strong Second Quarter Results 8Edwards Lifesciences Reports Strong Second Quarter Results 9Edwards Lifesciences Reports Strong Second Quarter Results 10Edwards Lifesciences Reports Strong Second Quarter Results 11Edwards Lifesciences Reports Strong Second Quarter Results 12Edwards Lifesciences Reports Strong Second Quarter Results 13Edwards Lifesciences Reports Strong Second Quarter Results 14Edwards Lifesciences Reports Strong Second Quarter Results 15Edwards Lifesciences Reports Strong Second Quarter Results 16Edwards Lifesciences Reports Strong Second Quarter Results 17Edwards Lifesciences Reports Strong Second Quarter Results 18Edwards Lifesciences Reports Strong Second Quarter Results 19Edwards Lifesciences Reports Strong Second Quarter Results 20Edwards Lifesciences Reports Strong Second Quarter Results 21Edwards Lifesciences Reports Strong Second Quarter Results 22Edwards Lifesciences Reports Strong Second Quarter Results 23Edwards Lifesciences Reports Strong Second Quarter Results 24Edwards Lifesciences Reports Strong Second Quarter Results 25New Technology May Improve Visualization Of The Brain During Stroke Treatment 2New Technology May Improve Visualization Of The Brain During Stroke Treatment 3
... July 13, 2011 ,   , ... quarter of 2011 Adjusted EBITDA margin is 19.8 ... Successful conclusion of refinancing , ... and healthcare industry, has closed successfully the second,quarter of the 2011 financial ...
... Jazz Pharmaceuticals, Inc. (Nasdaq: JAZZ ) today ... webcast on Thursday, July 28, 2011 at 4:30 p.m. Eastern ... provide a business and financial update and review second quarter ... release may be accessed from the Investors section of the ...
Cached Medicine Technology:Gerresheimer Reports Strong Revenues and Earnings Growth in the Second Quarter 2
(Date:7/29/2014)... The Board of Governors of the State Bar ... Connie Akridge to serve as a trustee of ... the Foundation. Akridge served as President of the State Bar ... Holland & Hart in Las Vegas, providing tailored counsel on ... and healthcare clients for more than 25 years. She regularly ...
(Date:7/29/2014)... D.C. (PRWEB) July 29, 2014 New ... in Medicare Part D by a projected $2.9 to ... by the actuarial firm Milliman released today by the ... Part D premiums could increase by as much as ... hepatitis C drugs, including Sovaldi and Olysio. , The ...
(Date:7/29/2014)... 2014 The Law Offices of Michael Cordova ... Hope, a non-profit organization providing grief camps for kids, teens, ... and suffering our clients experience from the death of a ... an organization like Stepping Stones of Hope, as they provide ... Stones of Hope also includes a monthly support group and ...
(Date:7/29/2014)... headache sufferers to record the severity and regularity of ... Griffith research study. , A new approach to the ... with their triggers and is being led by Professor ... Health program. , He has developed an approach designed ... their headaches called Learning to Cope with Triggers (LCT). ...
(Date:7/29/2014)... cure most cases of cancer is to surgically remove ... is that the surgeon may fail to extract the ... a new technique, researchers at the University of Pennsylvania ... the entire tumor in the patient, increasing the likelihood ... injectable dye that accumulates in cancerous tissues much more ...
Breaking Medicine News(10 mins):Health News:Holland & Hart LLP Attorney Connie Akridge Reappointed Trustee of the Nevada Bar Foundation 2Health News:New Milliman Study: Hepatitis C Drugs Could Increase Medicare Part D Spending by $2.9 to $5.8 Billion in 2015 2Health News:The Law Offices of Michael Cordova is Sponsoring Stepping Stones of Hope, a Non-Profit Organization Providing Grief Camps for Kids, Teens, Adults, and Families 2Health News:Penn team makes cancer glow to improve surgical outcomes 2Health News:Penn team makes cancer glow to improve surgical outcomes 3
... Both Jim Himes and,Rep. Chris Shays, candidates for US ... pledge to support a comprehensive,strategy to fight HIV/AIDS in ... of Connecticut are HIV-positive, and in 2006 there,were 422 ... the US,Centers for Disease Control. Approximately 56,000 people are ...
... PLYMOUTH MEETING, Pa., Oct. 29 Genaera,Corporation ... development partner,MedImmune, Inc. presented interim Phase 2a ... interleukin-9 (IL-9) in adults with mild,persistent asthma, ... meeting held,October 25-30 in Philadelphia, Pennsylvania., ...
... 29 The holiday season is here,which for most ... in homes bustling with family and friends. All of ... increased risk for contracting,viruses, particularly influenza. Maxim Health Systems ... they have not already done so, not only,to protect ...
... Skin Enterprises,Inc. (NYSE: NUS ) today announced ... million, a 7 percent improvement over the prior-year,period. ... improvement over the,same quarter of 2007. Revenue for ... currency fluctuations and earnings per share were,negatively impacted ...
... this year,s liver meeting in San ... Oct. 29 Two studies presented at the,annual meeting of ... different picture of survival based on racial group for adult ... College of Medicine used a United Network for,Organ Sharing dataset ...
... BEIJING, Oct. 29 /Xinhua-PRNewswire-FirstCall/ -- China Medical,Technologies, ... a leading China-based,medical device company that develops, ... today announced that it will be attending ... November 5, 2008, Location: Beijing, China, ...
Cached Medicine News:Health News:House Candidates Jim Himes and Chris Shays Pledge Action on HIV/AIDS Epidemic 2Health News:Phase 2a Data for MEDI-528 Presented at CHEST 2008 2Health News:Give the Gift of Good Health This Holiday Season - Remind Friends and Family to Get a Flu Shot 2Health News:Give the Gift of Good Health This Holiday Season - Remind Friends and Family to Get a Flu Shot 3Health News:Nu Skin Enterprises Reports Third-Quarter 2008 Results 2Health News:Nu Skin Enterprises Reports Third-Quarter 2008 Results 3Health News:Nu Skin Enterprises Reports Third-Quarter 2008 Results 4Health News:Nu Skin Enterprises Reports Third-Quarter 2008 Results 5Health News:Nu Skin Enterprises Reports Third-Quarter 2008 Results 6Health News:Nu Skin Enterprises Reports Third-Quarter 2008 Results 7Health News:Nu Skin Enterprises Reports Third-Quarter 2008 Results 8Health News:Nu Skin Enterprises Reports Third-Quarter 2008 Results 9Health News:Nu Skin Enterprises Reports Third-Quarter 2008 Results 10Health News:Nu Skin Enterprises Reports Third-Quarter 2008 Results 11Health News:No Difference in Rate of Survival for Children of Different Races Undergoing Liver Transplantation, but Long-Term Results Not as Good for African-American Adults 2Health News:No Difference in Rate of Survival for Children of Different Races Undergoing Liver Transplantation, but Long-Term Results Not as Good for African-American Adults 3
Used for retrograde positioning of a ureteral stent. The radiopaque band improves fluoroscopic visibility of the positioner tip. Supplied sterile in peel-open packages. Intended for one-time use....
... silicone or Silitek, ACMI Single J ... healing after surgery. Following cystectomy, the ... supports the ileal intestinal anastomosis, and ... leakage. Following ureteroscopy, the Single J ...
... for interoperative placement to stent ... construction and continent urinary diversions. ... Intended for one-time use. CAUTION: ... must not remain indwelling more ...
... Electrode provides ablation and hemostasis to minimize ... procedures. The V-Max Roller Bar electrode has ... have circular edges for high current density ... was developed to provide a smoother area ...
Medicine Products: